Holen Sie sich die Stockscreener-App
19.44
1.72%
-0.34
Handel nachbörslich:
19.05
-0.39
-2.01%
Schlusskurs vom Vortag:
$19.78
Offen:
$19.84
24-Stunden-Volumen:
1.04M
Relative Volume:
0.35
Marktkapitalisierung:
$899.37M
Einnahmen:
$82.71M
Nettoeinkommen (Verlust:
$-102.24M
KGV:
-5.297
EPS:
-3.67
Netto-Cashflow:
$-76.57M
1W Leistung:
-1.37%
1M Leistung:
+14.62%
6M Leistung:
+92.86%
1J Leistung:
+34.53%
1-Tages-Spanne:
$19.41
$19.99
1-Wochen-Bereich:
$18.65
$20.11
52-Wochen-Spanne:
$3.42
$21.02
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Vergleichen Sie URGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
19.44 | 897.52M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Price Channel Expanding on UroGen Pharma Ltd.’s ChartJuly 2025 Catalysts & Safe Capital Growth Plans - classian.co.kr
UroGen Pharma stock initiated at Overweight by Piper Sandler on Zusduri potential - Investing.com Australia
Urogen Pharma shares fall 1.49% premarket after Piper Sandler initiates coverage with an Overweight rating. - AInvest
UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN) - Seeking Alpha
Real Time Chart Alerts Flash Bullish on UroGen Pharma Ltd.Jobs Report & Weekly Watchlist for Hot Stocks - metrotimes.co.kr
Machine Learning Models Forecast UroGen Pharma Ltd. Uptick2025 Volatility Report & Real-Time Price Movement Reports - theviewers.co.kr
UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology - MSN
UroGen Pharma Ltd. Matches Institutional Buying FilterJuly 2025 WrapUp & Accurate Intraday Trade Tips - beatles.ru
UroGen (URGN) Q2 Revenue Rises 11% - AOL.com
Is UroGen Pharma Ltd. affected by consumer sentimentPortfolio Performance Report & Technical Buy Zone Confirmations - thegnnews.com
How UroGen Pharma Ltd. stock performs during market volatilityQuarterly Performance Summary & Technical Buy Zone Confirmations - beatles.ru
Why UroGen Pharma Ltd. stock attracts strong analyst attentionQuarterly Risk Review & Stock Timing and Entry Methods - sundaytimes.kr
UroGen Pharma Ltd. Trading Near Value Zone — Recovery AheadQuarterly Profit Summary & AI Optimized Trade Strategies - sundaytimes.kr
UroGen Pharma stock price target reiterated at $35 by TD Cowen - Investing.com India
UroGen Pharma CMO Schoenberg sells $176k in shares By Investing.com - Investing.com South Africa
Insider Sell: Mark Schoenberg Sells 10,000 Shares of UroGen Pharma Ltd (URGN) - GuruFocus
UroGen Pharma CMO Schoenberg sells $176k in shares - Investing.com India
UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript - Insider Monkey
UroGen Pharma price target lowered to $40 at H.C. Wainwright - Investing.com India
UroGen Pharma price target lowered to $40 at H.C. Wainwright By Investing.com - Investing.com Australia
URGN: HC Wainwright Lowers Price Target to $40.00, Maintains Buy Rating | URGN Stock News - GuruFocus
Can UroGen Pharma Ltd. disrupt its industryFastest Growing Stock Radar - newsyoung.net
The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
UroGen Pharma's Q2 2025 Earnings: A Catalyst for Valuation Re-Rating in Uro-Oncology? - AInvest
UroGen Pharma Q2 2025 Earnings Call Transcript - AInvest
UroGen Pharma Ltd. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:URGN) - Seeking Alpha
Oppenheimer Maintains Buy Rating on Urogen Pharma with $31 Price Target - AInvest
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI - TipRanks
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer - MSN
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $32 - 富途牛牛
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $31 - 富途牛牛
Guggenheim raises UroGen Pharma stock price target to $32 on Zusduri launch - Investing.com Nigeria
UroGen Pharma Q2 Earnings Call: FDA Approval, Revenue Growth, and Expanded Sales Force - AInvest
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA A - GuruFocus
UroGen Pharma Outpaces Forecasts With Revenue And FDA Nod - Finimize
Urogen Pharma Q2 2025 Earnings Call Transcript - MarketBeat
Health Care Stocks Slipped As Big Players Disappointed - Finimize
UroGen Pharma (URGN) Receives Consistent "Buy" Rating from D. Boral Capital | URGN Stock News - GuruFocus
Sector Update: Health Care - MarketScreener
UroGen Pharma Tops Revenue Forecasts With FDA Approval In Tow - Finimize
Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth - Investing.com
Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth By Investing.com - Investing.com South Africa
Urogen Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat - Investing.com
UroGen Pharma earnings missed by $0.22, revenue topped estimates - Investing.com Australia
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDUR - GuruFocus
Earnings Flash (URGN) UroGen Pharma Posts Q2 Net Loss $1.05 a Share, vs. FactSet Est of $0.83 Loss - MarketScreener
UroGen Pharma Ltd. SEC 10-Q Report - TradingView
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Urogen Pharma Ltd-Aktie (URGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Smith Jason Drew | General Counsel |
Jul 28 '25 |
Sale |
19.14 |
7,522 |
143,971 |
41,492 |
| Schoenberg Mark | Chief Medical Officer |
Jul 28 '25 |
Sale |
19.14 |
5,149 |
98,552 |
158,229 |
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):